Company Filing History:
Years Active: 2024
Title: The Innovations of Robert Miller
Introduction
Robert Miller is an accomplished inventor based in East Bridgewater, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of antibody-drug conjugates. His work focuses on enhancing the efficacy of treatments through innovative engineering techniques.
Latest Patents
Miller holds a patent for "Site-specific antibody-drug conjugation through glycoengineering." This patent provides binding polypeptides, such as antibodies, and effector moiety conjugates, including antibody-drug conjugates (ADCs). The invention features a site-specifically engineered drug-glycan linkage within native or engineered glycans of the binding polypeptide. Additionally, it includes nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors, and host cells for producing these polypeptides. The methods outlined in the patent aim to utilize these antigen-binding polypeptides for treating various diseases.
Career Highlights
Robert Miller is currently employed at Genzyme Corporation, a leading biotechnology company known for its innovative therapies. His role at Genzyme allows him to apply his expertise in glycoengineering and antibody-drug conjugation to develop advanced medical treatments.
Collaborations
Miller has collaborated with notable colleagues, including Clark Qun Pan and Qun Zhou. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.
Conclusion
Robert Miller's innovative work in antibody-drug conjugation through glycoengineering exemplifies the impact of biotechnology on modern medicine. His contributions continue to pave the way for new therapeutic approaches in treating diseases.